2nd Translational Research Conference
Acute Lymphoblastic Leukaemia
Chairs: Jan Cools, Hervé Dombret, Adele Fielding, Mark Litzov

2nd Translational Research Conference
Acute Lymphoblastic Leukaemia
Information
ABOUT THE CONFERENCE:
Major recent advances in the knowledge of the biological underpinning of acute lymphoblastic leukaemia (ALL) include the comprehensive description of B-cell precursor and T-cell ALL genomic landscapes, the identification of new potentially druggable disease subsets and the discovery of predisposing, preleukaemic events.
At the same time, the clinical management of the disease has improved in both children and adults thanks to the routine monitoring of measurable residual disease (MRD), the administration of intensified risk-adapted chemotherapy, the introduction of targeted therapies and antibodies, and the remarkable efficacy of antibody-drug conjugates (ADCs), bi-specific T-cell engager antibodies (BiTEs) and manufactured chimeric antigen receptor (CAR) T-cells.
This intense research activity has led to major improvements in patient outcome, while also providing important proofs of concept for the treatment of cancer in general. It has also made ALL a fascinating disease to study.
Submitted abstracts will be considered for presentation as Brief Oral Communications or Posters. Opportunities for exchange with the faculty include face-to-face live discussions during closed Meet the Expert sessions and during the plenary Mentored Poster Walks.
A strong emphasis will be placed on scientific discussion and debate throughout the meeting.
SCIENTIFIC TOPICS:
• Biology of B-cell precursor ALL
• Biology of T-cell ALL
• Minimal residual disease monitoring
• Individualized management of ALL
• New advances in ALL
• Car T-cells & allogeneic HSCT
• Frontline incorporation of BiTEs and ADCs
• T-cell ALL and lymphoblastic lymphoma
• Ph and PH-like ALL.
Programme
Read the final programme!
Corporate partners
With the support of*:


Level 2 E-Conference Partners
*******
*ESH conference programmes are developed in strict scientific independence
with no input from corporate sponsors.